Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by TopBrokeron Dec 30, 2020 2:30pm
119 Views
Post# 32198780

MANAGEMENT YEAR END EVALUATION

MANAGEMENT YEAR END EVALUATIONNow at year end is the time shareholders evaluate your managements record for the year. This is done for all Companies and not just yours, so the evaluation screen is quite simple in respect to shareholders:
1. Did your management team increase shareholders wealth?
2. Did your management team set the years objectives and meet those objectives?
3. Did your management team handle the Companies treasury in a prudent manner?
4. Did your management team get over compensated for performance?
5. Did your management team communicate with shareholders and portray realistic objectives?
6. Did your management team exceed or meet all their projected forecasts?

It is a yearly report card to evaluate whether or not you need a change oF Directors in the upcoming Shareholders meeting. I can tell you that this management team failed on all aspects of prudent management and only looked after themselves, in that regard i give them the CHRISTMAS FAIL.
<< Previous
Bullboard Posts
Next >>